Healthcare cost and policy

Pharma DTC marketing spend vs. Medicare negotiation savings

Originally posted by

Yesterday in a post I commented how the U.S. Pharma industry spends more on Direct to Consumer marketing than the savings announced as a result of the Medicare negotiations. That was in the context of discussing how I personally believe it’s red herring to say that paying fair prices for drugs in the US will harm R&D. (H/T to Tyler Renfro, APEB for the conversation.)

Today I open my notifications and see this. Let’s talk!

Originally posted on LinkedIn, where the discussion and source links live in the comments.

About the author

Chris Vanderwolk is Director of Compliance and Innovation at OneDigital | Kistler Tiffany Benefits General Agency, where he helps brokers and employers navigate the regulatory complexity of employee benefits. An ERISA attorney with more than 19 years in the benefits industry, he specializes in translating what the law actually requires into language people can use.

All writing